

Chr-A Polyclonal Antibody
Catalog # AP69099**Specification**

Chr-A Polyclonal Antibody - Product Information

Application	WB
Primary Accession	P10645
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal

Chr-A Polyclonal Antibody - Additional Information**Gene ID** 1113**Other Names**

CHGA; Chromogranin-A; CgA; Pituitary secretory protein I; SP-I

Dilution

WB~~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.

Format

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.

Storage Conditions

-20°C

Chr-A Polyclonal Antibody - Protein Information**Name** CHGA**Function**

[Pancreastatin]: Strongly inhibits glucose induced insulin release from the pancreas. [Serpinin]: Regulates granule biogenesis in endocrine cells by up-regulating the transcription of protease nexin 1 (SERPINE2) via a cAMP-PKA-SP1 pathway. This leads to inhibition of granule protein degradation in the Golgi complex which in turn promotes granule formation.

Cellular Location

[Serpinin]: Secreted {ECO:0000250|UniProtKB:P26339}. Cytoplasmic vesicle, secretory vesicle {ECO:0000250|UniProtKB:P26339}. Note=Pyroglutaminated serpinin localizes to secretory vesicle. {ECO:0000250|UniProtKB:P26339}

Tissue Location



Detected in cerebrospinal fluid (at protein level) (PubMed:25326458). Detected in urine (at protein level) (PubMed:37453717).


Chr-A Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Chr-A Polyclonal Antibody - Images





Chr-A Polyclonal Antibody - Background

Pancreastatin: Strongly inhibits glucose induced insulin release from the pancreas. Serpinin: Regulates granule biogenesis in endocrine cells by up-regulating the transcription of protease nexin 1 (SERPINE2) via a cAMP-PKA-SP1 pathway. This leads to inhibition of granule protein degradation in the Golgi complex which in turn promotes granule formation.